UM171 breaks new ground
Developed at UdeM, the molecule could soon be approved in Europe to treat blood cancers in patients without a compatible donor – a major step towards commercialization.
Developed at UdeM, the molecule could soon be approved in Europe to treat blood cancers in patients without a compatible donor – a major step towards commercialization.